Stock profile

DongKook Pharmaceutical Co., Ltd.(086450.KQ)

Country: South KoreaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: KOE
P/E TTM
12.3
History
P/E NTM
9.4
Market cap
865.22B
Currency KRW
KvantraRanki73
Value71
Quality87
Momentum58
Current price
20,450.00-5.32%
Benchmarks

No price history available.

Key financial summary

Financials in KRW
202020212022202320242025TTM2026E
Total revenueKRWm559,103594,193661,647730,994812,166926,884N/AN/A
Operating profitKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Net profitKRWm55,92550,34552,89647,17561,21966,020N/AN/A
EPS reportedKRWLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Net debtKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)KRWLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in KRW
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountrySouth Korea
Trades inKRW

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

DongKook Pharmaceutical Co., Ltd. (086450.KQ)

086450.KQ · KOE · Healthcare
20,450.00-5.32%
Sign up to track this stock

No price history available.

KvantraRank73
P/E TTM12.3
P/E NTM9.4
Market cap865.22B
KvantraRank?73 / 100
Value
71
Quality
87
Momentum
58
Financialsin KRW
20242025TTM2026E
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountrySouth Korea
Trades inKRW

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans